EA200702161A1 - Кристаллическая форма хинолинон-карбоксамидного соединения - Google Patents

Кристаллическая форма хинолинон-карбоксамидного соединения

Info

Publication number
EA200702161A1
EA200702161A1 EA200702161A EA200702161A EA200702161A1 EA 200702161 A1 EA200702161 A1 EA 200702161A1 EA 200702161 A EA200702161 A EA 200702161A EA 200702161 A EA200702161 A EA 200702161A EA 200702161 A1 EA200702161 A1 EA 200702161A1
Authority
EA
Eurasian Patent Office
Prior art keywords
quinolinon
crystal form
carboxamide compound
salt forms
crystalline
Prior art date
Application number
EA200702161A
Other languages
English (en)
Other versions
EA012115B1 (ru
Inventor
Пол Р. Фазери
С. Дерек Тернер
Адам Голдблум
Роберт Чао
Дэниэл Дженов
Original Assignee
Тереванс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тереванс, Инк. filed Critical Тереванс, Инк.
Publication of EA200702161A1 publication Critical patent/EA200702161A1/ru
Publication of EA012115B1 publication Critical patent/EA012115B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к кристаллическому гидрохлориду {(1S,3R,5R)-8-[(R)-2-гидрокси-3- (метансульфонилметиламино)пропил]-8-азабицикло[3.2.1]окт-3-ил}амида 1-изопропил-2-оксо-1,2-дигидрохинолин-3-карбоновой кислоты или сольвату этой соли. Изобретение также предлагает фармацевтические композиции, содержащие такие кристаллические солевые формы, способы применения таких кристаллических солевых форм для лечения расстройств, ассоциированных с активностью рецепторов 5-НТ, а также способы получения таких кристаллических солевых форм.
EA200702161A 2005-04-06 2006-04-05 Кристаллическая форма хинолинон-карбоксамидного соединения EA012115B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (2)

Publication Number Publication Date
EA200702161A1 true EA200702161A1 (ru) 2008-04-28
EA012115B1 EA012115B1 (ru) 2009-08-28

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702161A EA012115B1 (ru) 2005-04-06 2006-04-05 Кристаллическая форма хинолинон-карбоксамидного соединения

Country Status (30)

Country Link
US (4) US7728004B2 (ru)
EP (1) EP1874766B1 (ru)
JP (2) JP5230407B2 (ru)
KR (1) KR101322873B1 (ru)
CN (1) CN101151264B (ru)
AR (2) AR053208A1 (ru)
AT (1) ATE479682T1 (ru)
AU (1) AU2006232129B2 (ru)
BR (1) BRPI0610657A2 (ru)
CA (1) CA2603654C (ru)
CY (1) CY1111275T1 (ru)
DE (1) DE602006016586D1 (ru)
DK (1) DK1874766T3 (ru)
EA (1) EA012115B1 (ru)
ES (1) ES2350495T3 (ru)
HK (1) HK1110866A1 (ru)
HR (1) HRP20100629T1 (ru)
IL (1) IL186023A (ru)
MA (1) MA29403B1 (ru)
MX (1) MX2007012438A (ru)
MY (1) MY151075A (ru)
NO (1) NO339699B1 (ru)
NZ (1) NZ561900A (ru)
PE (1) PE20061310A1 (ru)
PL (1) PL1874766T3 (ru)
PT (1) PT1874766E (ru)
SI (1) SI1874766T1 (ru)
TW (1) TWI377206B (ru)
WO (1) WO2006108127A2 (ru)
ZA (1) ZA200708071B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
EP1807423B1 (en) 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
SI2404919T1 (sl) 2005-11-08 2013-12-31 Vertex Pharmaceuticals Incorporated Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス， インコーポレーテッド 腸の前処置のための運動促進剤
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
KR20150063170A (ko) 2007-12-07 2015-06-08 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
MX2011010782A (es) 2009-04-13 2012-01-20 Theravance Inc Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
ES2865600T3 (es) 2013-11-12 2021-10-15 Vertex Pharma Proceso de preparación de composiciones farmacéuticas para el tratamiento de enfermedades mediadas por CFTR
EP3661518A1 (en) * 2017-07-31 2020-06-10 Theravance Biopharma R&D IP, LLC Methods of treating symptoms of gastroparesis using velusetrag
WO2024061960A1 (en) 2022-09-20 2024-03-28 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
CA2097815C (en) * 1990-12-28 2001-04-17 Fumio Suzuki Quinoline derivative
EP0670319A4 (en) * 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
EP1689742B1 (en) 2003-11-24 2010-03-17 Pfizer, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
US20060183901A1 (en) 2005-02-17 2006-08-17 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
US7446114B2 (en) * 2005-03-02 2008-11-04 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
CN101151264B (zh) 2011-07-06
WO2006108127A3 (en) 2007-01-04
HRP20100629T1 (hr) 2010-12-31
EP1874766A2 (en) 2008-01-09
IL186023A0 (en) 2008-01-20
JP2012153725A (ja) 2012-08-16
CN101151264A (zh) 2008-03-26
US20140256769A1 (en) 2014-09-11
KR20070116988A (ko) 2007-12-11
IL186023A (en) 2011-09-27
BRPI0610657A2 (pt) 2010-07-13
PE20061310A1 (es) 2007-01-23
CA2603654A1 (en) 2006-10-12
ES2350495T3 (es) 2011-01-24
PT1874766E (pt) 2010-11-30
DE602006016586D1 (de) 2010-10-14
CY1111275T1 (el) 2015-08-05
AR053208A1 (es) 2007-04-25
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
MY151075A (en) 2014-03-31
TWI377206B (en) 2012-11-21
TW200643020A (en) 2006-12-16
ZA200708071B (en) 2008-10-29
AR110019A2 (es) 2019-02-13
US7728004B2 (en) 2010-06-01
SI1874766T1 (sl) 2010-12-31
AU2006232129A1 (en) 2006-10-12
KR101322873B1 (ko) 2013-10-30
ATE479682T1 (de) 2010-09-15
NZ561900A (en) 2010-12-24
EA012115B1 (ru) 2009-08-28
MX2007012438A (es) 2007-12-05
US20160095849A1 (en) 2016-04-07
US9126994B2 (en) 2015-09-08
NO20075574L (no) 2007-11-02
AU2006232129B2 (en) 2012-07-12
HK1110866A1 (en) 2008-07-25
JP5230407B2 (ja) 2013-07-10
WO2006108127A2 (en) 2006-10-12
MA29403B1 (fr) 2008-04-01
PL1874766T3 (pl) 2011-02-28
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
CA2603654C (en) 2014-05-27
US20100197728A1 (en) 2010-08-05
US20060229332A1 (en) 2006-10-12
NO339699B1 (no) 2017-01-23
JP2008535848A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
EA200702161A1 (ru) Кристаллическая форма хинолинон-карбоксамидного соединения
TW200800981A (en) 8-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonists
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
WO2004106279A3 (en) CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST
TW200640921A (en) Crystalline form of an indazole-carboxamide compound
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
WO2012048129A3 (en) Inhibitors of polo-like kinase
EA201370184A1 (ru) Гетероарильные производные
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
MX2009009141A (es) Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano.
TN2012000132A1 (en) N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
EA200900244A1 (ru) Модуляторы активности хемокиновых рецепторов, их кристаллические формы и способ их получения
NO20090190L (no) Modulatorer av kjemokin reseptor aktivitet, krystallinske former og fremgangsmate
EA200970432A1 (ru) 8-сульфонил-1,3,4,8-тетрагидро-2н-[1,4]оксазепино[6,7-e] индольные производные и их использование в качестве 5-нт6 рецепторных лигандов
SG165397A1 (en) Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8- aminocaprylic acid
MY179041A (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
MX2011013149A (es) Acido (s)-2-bencil-3-((3r,4r)-4 - (3 - carbamoilfenil) -3,4-dimetilpiperidinil) propanoico y sales delmismo como antagonistas de receptores opioides.
BR112015007991A2 (pt) derivados de etinila como moduladores da atividade do receptor de mglur5
BR122020008947B1 (pt) Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do receptor glutamatérgico metabotrópico do subtipo 2, composição farmacêutica, e seus usos
WO2006106432A8 (en) 4-arylpiperidine derivatives and use thereof for preparing a medicament for the treatment of cns disorders
TH120971A (th) รูปแบบเชิงผลึกของสารประกอบ 8-อะซาไบไซโคล[3.2.1]ออกเทน
TH120971B (th) รูปแบบเชิงผลึกของสารประกอบ 8-อะซาไบไซโคล[3.2.1]ออกเทน

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment